PACT (Platelet Activity After Clopidogrel Termination) — PACT  

Clopidogrel Clinical Trial

Official title: PACT (Platelet Activity After Clopidogrel Termination)

Status Completed

Clinical Trial Summary

Clopidogrel is a medication that is used to decrease the ability of platelets to form blood clots.

The theory has been proposed that, in patients with coronary artery disease or stroke, increased platelet function after discontinuation of clopidogrel therapy is associated with an increased clotting risk. However, this theory has never been rigorously tested.

The goal of this research is to determine whether discontinuation of clopidogrel results in increased platelet function.

Clinical Trial Description

In this study, we will address the question: does discontinuation of clopidogrel result in platelet hyperreactivity? We will perform a double-blind, placebo-controlled, crossover study in normal subjects, in whom platelet reactivity will be measured before clopidogrel or placebo, during clopidogrel or placebo, and at various time points after discontinuation of clopidogrel or placebo. The dose of clopidogrel will be the standard, FDA-approved dose: 75 mg daily. All subjects will be treated with aspirin 81 mg daily throughout the 57 days of study assessment in both the clopidogrel arm and the placebo arm, because the clinically relevant question is: in patients who remain on aspirin, does discontinuation of clopidogrel result in platelet hyperreactivity? ;

Related Conditions & MeSH terms

• Blood Platelets
• Clopidogrel

• NCT number: NCT00619073
• Study type: Interventional
• Source: University of Massachusetts, Worcester
• Status: Completed
• Phase: N/A
• Start date: April 2008
• Completion date: May 2009